Cancers Hijack Immune Surveillance and Tumor Microenvironment Leading to Immune Evasion
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: 31 July 2025 | Viewed by 132
Special Issue Editors
Interests: anti-tumor immunity; cancer immunotherapy; immune evasion; immune response modulation; immunosuppression; immune surveillance; manipulating IR components function and migration; metabolic modulation of the TME; metabolic reprogramming; tumor-associated immune cells; tumor microenvironment (TME)
Special Issues, Collections and Topics in MDPI journals
Interests: investigation of immunosuppressive mechanisms and development of innovative immunotherapeutic strategies for human malignant melanoma using in particular transgenic mouse melanoma model
Interests: inflammation; neutrophils; nets; neutrophil extracellular traps; plasma membrane; nanoparticles; adjuvants; SARS-CoV-2; vaccines; coronavirus; glycans; igg; cell death; in vivo imaging; ros; ros amplifiers; prodrugs
Special Issue Information
Dear Colleagues,
Since the 1980s, when W. Coley suggested that it is possible to combat cancer by activating the immune response, it took about 130 years for the immune response to establish itself as a crucial anti-tumor component.
Yet, tumors employ various mechanisms to evade or counteract attack by immune response components. Some of these mechanisms involve changes in the manifestation of tumor cells, others modulate the immune cells directly, and some affect the tumor microenvironment. The following are examples of such mechanisms:
- Changes in tumor cells can include the loss of antigens, the loss of HLA components, and danger signals; alterations in the expression of immunomodulatory ligands on the cancer cell surface; defects in damage-associated molecular pattern (DAMP) or type I interferon (IFN) signaling; the upregulation of negative immune checkpoints; and the impairment of the expression of pattern recognition receptor (PRR).
- Direct modulation of immune cells includes a reduction in pro-inflammatory cytokine signaling and inhibition of the recruitment of immune components to inhibit anti-cancer immune attack; the release of factors that dampen the function of immune cells; promotion of the activity of immunosuppressive cells, such as regulatory T (Treg) cells, TAMs, and MDSCs; suppression of the activity of immune effector cells by the secretion of TGFb, prostaglandin E2 (PGE2), IL-10, etc.
- Mechanisms that affect the tumor microenvironment include metabolic reprogramming, which may cause alterations in the cancer cell cytokine and metabolite secretion, such as the over-secretion of vascular endothelial growth factor A (VEGFA).
Prof. Dr. Yona K. Keisari
Prof. Dr. Viktor Umansky
Prof. Dr. Rostyslav Bilyy
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- anti-tumor immunity
- cancer immunotherapy
- immune evasion
- immune response modulation
- immunosuppression
- immune surveillance
- manipulating IR components function and migration
- metabolic modulation of the TME
- metabolic reprogramming
- tumor-associated immune cells
- tumor microenvironment (TME)
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
